These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6105023)

  • 1. Thyrotrophin binding inhibiting immunoglobulins in Graves' disease before, during and after antithyroid therapy, and its relation to long-acting thyroid stimulator.
    Docter R; Bos G; Visser TJ; Hennemann G
    Clin Endocrinol (Oxf); 1980 Feb; 12(2):143-53. PubMed ID: 6105023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of the mouse thyrotrophin receptor with thyrotrophin binding inhibitor immunoglobulins.
    Luttrell BM
    J Endocrinol; 1983 Mar; 96(3):481-8. PubMed ID: 6131925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease.
    Cho BY; Shong MH; Yi KH; Lee HK; Koh CS; Min HK
    Clin Endocrinol (Oxf); 1992 Jun; 36(6):585-90. PubMed ID: 1358483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Studies on the radioreceptor assay of TSH: the properties of TSH-binding inhibitor immunoglobulins (TBII) in patients with Graves' disease (author's transl)].
    Endo K
    Nihon Naibunpi Gakkai Zasshi; 1979 Oct; 55(10):1261-74. PubMed ID: 228998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of thyrotrophin binding inhibiting immunoglobulins (TBII) in longterm antithyroid treatment, 131I therapy given in combination with carbimazole and in euthyroid ophthalmopathy.
    Bliddal H; Kirkegaard C; Siersbaek-Nielsen K; Friis T
    Acta Endocrinol (Copenh); 1981 Nov; 98(3):364-9. PubMed ID: 6170200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis.
    Endo K; Kasagi K; Konishi J; Ikekubo K; Okuno T; Takeda Y; Mori T; Torizuka K
    J Clin Endocrinol Metab; 1978 May; 46(5):734-9. PubMed ID: 45421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease.
    Tamaki H; Amino N; Iwatani Y; Tachi J; Kimura M; Mitsuda N; Ichihara K; Tanizawa O; Miyai K
    Clin Endocrinol (Oxf); 1989 May; 30(5):493-503. PubMed ID: 2575017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The assay of Graves' immunoglobulins: a comparison of different methods.
    Hardisty CA; Kendall-Taylor P; Atkinson S; Humphries H; Munro DS
    Clin Endocrinol (Oxf); 1983 Jun; 18(6):637-44. PubMed ID: 6136348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A stable, reproducible radioreceptorassay for thyrotropin binding inhibiting immunoglobulins (TBII).
    Bliddal H
    Scand J Clin Lab Invest; 1981 Sep; 41(5):441-9. PubMed ID: 6118939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.
    Hörmann R; Saller B; Müller R; Mann K
    Klin Wochenschr; 1985 Dec; 63(24):1247-52. PubMed ID: 2868149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of parallel measurements of thyrotropin binding inhibiting immunoglobulins (TBII) and thyroid adenylate cyclase stimulating antibodies (TSAb) in Graves' disease after longterm antithyroid treatment.
    Bliddal H; Bech K; Siersbaek-Nielsen K; Friis T
    J Endocrinol Invest; 1983 Aug; 6(4):259-62. PubMed ID: 6139399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between thyroid stimulating and tsh-binding inhibiting immunoglobulins of Graves' disease.
    Macchia E; Fenzi GF; Monzani F; Lippi F; Vitti P; Grasso L; Bartalena L; Baschieri L; Pinchera A
    Clin Endocrinol (Oxf); 1981 Aug; 15(2):175-82. PubMed ID: 6118213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods.
    Morris JC; Hay ID; Nelson RE; Jiang NS
    Mayo Clin Proc; 1988 Jul; 63(7):707-17. PubMed ID: 2898572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease.
    Kasagi K; Hatabu H; Tokuda Y; Iida Y; Endo K; Konishi J
    Clin Endocrinol (Oxf); 1988 Oct; 29(4):357-66. PubMed ID: 2908031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of a correlation between thyrotrophin receptor binding inhibition and thyroid adenylate cyclase activation by immunoglobulins in Graves' disease before and during long-term antithyroid treatment.
    Bliddal H; Bech K; Hyltoft Petersen P; Siersbaek-Nielsen K; Friis T
    Acta Endocrinol (Copenh); 1982 Sep; 101(1):35-40. PubMed ID: 6181640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graves' disease in pregnancy: TSH receptor binding inhibiting immunoglobulins and maternal and neonatal thyroid function.
    Mortimer RH; Tyack SA; Galligan JP; Perry-Keene DA; Tan YM
    Clin Endocrinol (Oxf); 1990 Feb; 32(2):141-52. PubMed ID: 1971773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.